# Regulatory Submission Checklist Template

**Product Name:** [Product Name]  
**Submission Type:** [NDA/ANDA/BLA/MAA/etc.]  
**Target Authority:** [FDA/EMA/PMDA/etc.]  
**Submission Date:** [YYYY-MM-DD]  
**Version:** [1.0]  
**Prepared By:** [Name/Title]  
**Approved By:** [Name/Title]

## ğŸ“‹ Instructions for Use

This checklist serves as a comprehensive guide for preparing regulatory submissions to health authorities. Use this template to ensure all required components are included and properly formatted before submission.

**Status Key:**
- ğŸ“ Not Started
- â³ In Progress
- âœ… Complete
- âŒ Not Applicable
- âš ï¸ Issues Identified

**Validation Required:**
- ğŸ” Document Review
- ğŸ‘¥ Peer Review
- ğŸ‘¤ SME Review
- ğŸ“Š Data Verification
- ğŸ”„ Cross-Reference Check

---

## 1. Administrative Documentation

| Item | Description | Status | Responsible Person | Due Date | Validation Required | Comments |
|------|-------------|--------|-------------------|----------|---------------------|----------|
| 1.1 | **Cover Letter** <br>*Includes purpose of submission, brief product description, and reference to related submissions* | ğŸ“ | [Name] | [Date] | ğŸ” | |
| 1.2 | **Application Form** <br>*Appropriate form for jurisdiction (e.g., FDA Form 356h, EU Application Form)* | ğŸ“ | [Name] | [Date] | ğŸ”ğŸ‘¥ | |
| 1.3 | **Administrative Information** <br>*Contact details for sponsor and authorized representatives* | ğŸ“ | [Name] | [Date] | ğŸ” | |
| 1.4 | **User Fee Payment Confirmation** <br>*Receipt or proof of payment* | ğŸ“ | [Name] | [Date] | ğŸ” | |
| 1.5 | **Patent Information/Certifications** <br>*Form FDA 3542a or equivalent* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 1.6 | **Financial Disclosure Information** <br>*Form FDA 3454/3455 or equivalent* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 1.7 | **Request for Proprietary Name Review** <br>*If applicable* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 1.8 | **Letters of Authorization** <br>*For referenced information (e.g., DMFs)* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 1.9 | **Statement of Right of Reference** <br>*If relying on data submitted by others* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 1.10 | **Statements of Compliance** <br>*GCP, GLP, GMP certifications* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |

> **Guidance Note:** Ensure all forms are current versions from regulatory authority websites. The cover letter should clearly state the type of submission and highlight any special requests (expedited review, waivers, etc.).

> **Example - Cover Letter Essential Elements:**
> - Clear identification of submission type and product
> - Brief product description and indication
> - List of all modules/sections included
> - Reference to previous related submissions
> - Special requests (priority review, etc.)
> - Contact information for questions

---

## 2. Product Information and Technical Documentation

| Item | Description | Status | Responsible Person | Due Date | Validation Required | Comments |
|------|-------------|--------|-------------------|----------|---------------------|----------|
| 2.1 | **Product Labels and Packaging** <br>*All components including carton, container, package insert* | ğŸ“ | [Name] | [Date] | ğŸ”ğŸ‘¥ğŸ‘¤ | |
| 2.2 | **Prescribing Information/SmPC** <br>*Full proposed text with tracked changes if updates* | ğŸ“ | [Name] | [Date] | ğŸ”ğŸ‘¥ğŸ‘¤ | |
| 2.3 | **Patient Information Leaflet** <br>*In appropriate lay language* | ğŸ“ | [Name] | [Date] | ğŸ”ğŸ‘¥ | |
| 2.4 | **Summary of Product Characteristics** <br>*For EU submissions* | ğŸ“ | [Name] | [Date] | ğŸ”ğŸ‘¥ğŸ‘¤ | |
| 2.5 | **Environmental Assessment** <br>*Or claim for categorical exclusion* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 2.6 | **Risk Management Plan/REMS** <br>*Detailed safety monitoring and risk minimization* | ğŸ“ | [Name] | [Date] | ğŸ”ğŸ‘¥ğŸ‘¤ | |
| 2.7 | **Product Quality Review** <br>*Overall summary of quality aspects* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |
| 2.8 | **Comparison to Reference Product** <br>*For generics/biosimilars* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |
| 2.9 | **Quality Overall Summary** <br>*CTD Module 2.3* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |

> **Guidance Note:** Product labeling must comply with region-specific requirements (e.g., FDA Pregnancy and Lactation Labeling Rule, EU QRD template). Ensure all prescribing information is consistent with clinical data.

> **Example - Risk Management Plan Key Components:**
> - Safety specifications
> - Pharmacovigilance plan
> - Risk minimization measures
> - Evaluation of effectiveness of risk minimization
> - Summary of changes from previous versions

---

## 3. Clinical Data Requirements

| Item | Description | Status | Responsible Person | Due Date | Validation Required | Comments |
|------|-------------|--------|-------------------|----------|---------------------|----------|
| 3.1 | **Clinical Overview** <br>*CTD Module 2.5 - Benefit/risk assessment* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |
| 3.2 | **Clinical Summary** <br>*CTD Module 2.7 - Biopharmaceutics, clinical pharmacology, efficacy, safety* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |
| 3.3 | **Clinical Study Reports** <br>*All pivotal studies with appropriate appendices* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“ŠğŸ”„ | |
| 3.4 | **Case Report Forms** <br>*For deaths, SAEs, discontinuations* | ğŸ“ | [Name] | [Date] | ğŸ‘¥ğŸ“Š | |
| 3.5 | **Patient Data Listings** <br>*Individual patient data in appropriate format* | ğŸ“ | [Name] | [Date] | ğŸ“Š | |
| 3.6 | **Statistical Analysis Documentation** <br>*Analysis plans, datasets, programs* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |
| 3.7 | **Literature References** <br>*Copies of key publications cited* | ğŸ“ | [Name] | [Date] | ğŸ”ğŸ”„ | |
| 3.8 | **Post-marketing Experience Reports** <br>*For marketed products* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 3.9 | **Integrated Summary of Efficacy** <br>*For US submissions* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |
| 3.10 | **Integrated Summary of Safety** <br>*For US submissions* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |

> **Guidance Note:** Ensure all clinical study reports follow ICH E3 format. All efficacy and safety claims in product labeling must be supported by data in this section.

> **Example - Clinical Study Report Checklist:**
> - ICH E3 compliant format
> - All required signatures obtained
> - Protocol deviations documented and explained
> - Statistical methods clearly described
> - Primary and secondary endpoints analyzed per protocol
> - Safety data comprehensively presented
> - Appropriate appendices included

---

## 4. Non-Clinical Data Requirements

| Item | Description | Status | Responsible Person | Due Date | Validation Required | Comments |
|------|-------------|--------|-------------------|----------|---------------------|----------|
| 4.1 | **Nonclinical Overview** <br>*CTD Module 2.4 - Integrated assessment of pharmacology, PK, toxicology* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 4.2 | **Nonclinical Summary** <br>*CTD Module 2.6 - Written and tabulated summaries* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 4.3 | **Pharmacology Study Reports** <br>*Primary pharmacodynamics, secondary pharmacodynamics, safety pharmacology* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |
| 4.4 | **Pharmacokinetic Study Reports** <br>*ADME studies in relevant species* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |
| 4.5 | **Toxicology Study Reports** <br>*Single and repeat dose, genotoxicity, carcinogenicity, reproductive toxicity* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |
| 4.6 | **Local Tolerance Studies** <br>*As applicable to route of administration* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 4.7 | **Special Toxicity Studies** <br>*Immunotoxicity, dependence, metabolites, impurities* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 4.8 | **GLP Compliance Statements** <br>*For all pivotal toxicology studies* | ğŸ“ | [Name] | [Date] | ğŸ” | |

> **Guidance Note:** All pivotal toxicology studies must be GLP-compliant. For biologics, special considerations for immunogenicity assessment should be included.

> **Example - Toxicology Battery for Small Molecule NDA:**
> - 2 species (rodent and non-rodent) repeat-dose studies
> - Duration supporting intended clinical use
> - Complete genotoxicity battery
> - Carcinogenicity studies (if treatment >6 months)
> - Complete reproductive toxicology package
> - Special toxicity studies for specific concerns

---

## 5. CMC Documentation

| Item | Description | Status | Responsible Person | Due Date | Validation Required | Comments |
|------|-------------|--------|-------------------|----------|---------------------|----------|
| 5.1 | **Drug Substance Information** <br>*Manufacturing, characterization, controls* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |
| 5.2 | **Drug Product Information** <br>*Composition, manufacturing, controls* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |
| 5.3 | **Analytical Procedures and Validation** <br>*Method descriptions and validation reports* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |
| 5.4 | **Batch Analysis Results** <br>*For representative batches* | ğŸ“ | [Name] | [Date] | ğŸ“Š | |
| 5.5 | **Reference Standards Information** <br>*Characterization and CoA* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 5.6 | **Container Closure System** <br>*Description and qualification* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 5.7 | **Stability Data** <br>*Long-term, accelerated, stress conditions* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |
| 5.8 | **Process Validation Reports** <br>*Or validation plan for commercial scale* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 5.9 | **Excipient Information** <br>*Novel excipients or new routes of administration* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 5.10 | **Manufacturing Facilities Information** <br>*Sites, functions, GMP compliance* | ğŸ“ | [Name] | [Date] | ğŸ” | |

> **Guidance Note:** CMC information should follow ICH Q guidelines. For biologics, additional characterization and comparability data may be required.

> **Example - Stability Data Requirements:**
> - Minimum of 3 batches
> - Primary stability batches on final commercial process
> - Container closure system identical to commercial
> - Testing at all time points per ICH guidelines
> - Statistical evaluation of data
> - Proposed shelf-life and storage conditions justified by data

---

## 6. Regional-Specific Requirements

### 6.1 FDA (United States)

| Item | Description | Status | Responsible Person | Due Date | Validation Required | Comments |
|------|-------------|--------|-------------------|----------|---------------------|----------|
| 6.1.1 | **Integrated Summary of Effectiveness (ISE)** | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |
| 6.1.2 | **Integrated Summary of Safety (ISS)** | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |
| 6.1.3 | **Pediatric Study Plan/Waiver Request** | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 6.1.4 | **Risk Evaluation and Mitigation Strategy (REMS)** <br>*If applicable* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 6.1.5 | **Electronic Datasets (CDISC Compliant)** | ğŸ“ | [Name] | [Date] | ğŸ“Š | |
| 6.1.6 | **Abuse Potential Assessment** <br>*For CNS-active compounds* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |

### 6.2 EMA (European Union)

| Item | Description | Status | Responsible Person | Due Date | Validation Required | Comments |
|------|-------------|--------|-------------------|----------|---------------------|----------|
| 6.2.1 | **Summary of Product Characteristics (SmPC)** | ğŸ“ | [Name] | [Date] | ğŸ”ğŸ‘¥ğŸ‘¤ | |
| 6.2.2 | **Paediatric Investigation Plan (PIP)** | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 6.2.3 | **Environmental Risk Assessment** | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 6.2.4 | **QRD Compliant Labeling** | ğŸ“ | [Name] | [Date] | ğŸ” | |
| 6.2.5 | **Pharmacovigilance System Master File (PSMF) Summary** | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 6.2.6 | **Risk Management Plan (EU-RMP)** | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |

### 6.3 PMDA (Japan)

| Item | Description | Status | Responsible Person | Due Date | Validation Required | Comments |
|------|-------------|--------|-------------------|----------|---------------------|----------|
| 6.3.1 | **Module 1 in Japanese** | ğŸ“ | [Name] | [Date] | ğŸ”ğŸ‘¥ | |
| 6.3.2 | **Japanese Clinical Data** <br>*Or bridging strategy* | ğŸ“ | [Name] | [Date] | ğŸ‘¤ğŸ“Š | |
| 6.3.3 | **Quality Data Meeting Japanese Pharmacopoeia** | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |
| 6.3.4 | **Risk Management Plan (J-RMP)** | ğŸ“ | [Name] | [Date] | ğŸ‘¤ | |

> **Guidance Note:** Regional requirements vary significantly. Consult current regulatory guidelines for the specific authority. Pre-submission meetings are highly recommended to confirm expectations.

> **Example - FDA-EMA Differences:**
> - FDA requires Integrated Summaries (ISE/ISS), EMA does not
> - FDA datasets must be CDISC-compliant (SDTM/ADaM)
> - EU requires more extensive Environmental Risk Assessment
> - Format differences in prescribing information (USPI vs SmPC)
> - Different pediatric requirements (PSP vs PIP)

---

## 7. Electronic Submission Format Requirements

| Item | Description | Status | Responsible Person | Due Date | Validation Required | Comments |
|------|-------------|--------|-------------------|----------|---------------------|----------|
| 7.1 | **eCTD Structure and Navigation** <br>*Proper hierarchy, ToC, hyperlinks* | ğŸ“ | [Name] | [Date] | ğŸ”ğŸ”„ | |
| 7.2 | **PDF Requirements** <br>*PDF version, bookmarks, hyperlinks* | ğŸ“ | [Name] | [Date] | ğŸ” | |
| 7.3 | **File Naming Conventions** <br>*Per regional guidelines* | ğŸ“ | [Name] | [Date] | ğŸ” | |
| 7.4 | **Appropriate Granularity** <br>*Document chunking strategy* | ğŸ“ | [Name] | [Date] | ğŸ” | |
| 7.5 | **Study Tagging Files (STFs)** <br>*For clinical studies* | ğŸ“ | [Name] | [Date] | ğŸ” | |
| 7.6 | **XML Backbone Validation** <br>*DTD compliance* | ğŸ“ | [Name] | [Date] | ğŸ” | |
| 7.7 | **Electronic Datasets** <br>*Format compliance (CDISC, etc.)* | ğŸ“ | [Name] | [Date] | ğŸ“Š | |
| 7.8 | **Technical Validation Report** <br>*From eCTD publishing tool* | ğŸ“ | [Name] | [Date] | ğŸ” | |

> **Guidance Note:** Electronic format requirements are region-specific and updated regularly. Refer to the latest technical specifications from each authority.

> **Example - PDF Requirements:**
> - PDF version 1.4 to 1.7
> - No security settings or password protection
> - Fonts embedded and subsetted
> - Bookmarks for document navigation
> - Hyperlinks for cross-references
> - Page orientation set correctly
> - No attachments within PDFs

---

## 8. Quality Control Checks

| Item | Description | Status | Responsible Person | Due Date | Validation Required | Comments |
|------|-------------|--------|-------------------|----------|---------------------|----------|
| 8.1 | **Technical Document Review** <br>*Format, pagination, cross-references* | ğŸ“ | [Name] | [Date] | ğŸ” | |
| 8.2 | **Content Consistency Check** <br>*Across all sections* | ğŸ“ | [Name] | [Date] | ğŸ”ğŸ‘¥ğŸ”„ | |
| 8.3 | **Labeling Consistency Check** <br>*With clinical and nonclinical data* | ğŸ“ | [Name] | [Date] | ğŸ”ğŸ‘¥ğŸ”„ | |
| 8.4 | **Hyperlinking Validation** <br>*All hyperlinks functional* | ğŸ“ | [Name] | [Date] | ğŸ” | |
| 8.5 | **Technical Validation** <br>*eCTD validator results* | ğŸ“ | [Name] | [Date] | ğŸ” | |
| 8.6 | **Spelling and Grammar Check** <br>*All documents* | ğŸ“ | [Name] | [Date] | ğŸ” | |
| 8.7 | **Table of Contents Accuracy** <br>*Page numbers, sections* | ğŸ“ | [Name] | [Date] | ğŸ” | |
| 8.8 | **Pre-submission Review** <br>*Final QC before submission* | ğŸ“ | [Name] | [Date] | ğŸ”ğŸ‘¥ | |

> **Guidance Note:** A thorough QC process is critical to submission success. Consider using specialized eCTD validation software and multiple independent reviewers.

> **Example - Pre-submission Review Checklist:**
> - Validate technical eCTD compliance
> - Check all hyperlinks and bookmarks
> - Verify cross-references between documents
> - Confirm consistency between summaries and detailed data
> - Ensure all required signatures are present
> - Verify all tracked changes have been accepted/rejected
> - Check for orphan references or hanging cross-references

---

## 9. Submission Readiness Assessment

| Review Level | Reviewer | Date Completed | Status | Comments |
|-------------|----------|----------------|--------|----------|
| **Technical Review** <br>(eCTD format, hyperlinks, etc.) | [Name] | [Date] | ğŸ“ | |
| **Content Review** <br>(Scientific accuracy, completeness) | [Name] | [Date] | ğŸ“ | |
| **Regulatory Strategy Review** <br>(Compliance with regulations) | [Name] | [Date] | ğŸ“ | |
| **Editorial Review** <br>(Language, formatting) | [Name] | [Date] | ğŸ“ | |
| **Senior Management Review** <br>(Final approval) | [Name] | [Date] | ğŸ“ | |

## Final Approval for Submission

| Role | Name | Signature | Date |
|------|------|-----------|------|
| Regulatory Affairs Lead | | | |
| Quality Assurance | | | |
| Clinical Lead | | | |
| CMC Lead | | | |
| Legal Representative | | | |

---

## Post-Submission Tracking

| Milestone | Expected Date | Actual Date | Status | Comments |
|-----------|---------------|-------------|--------|----------|
| Submission Acknowledgement | [Date] | | ğŸ“ | |
| Validation/Filing Review | [Date] | | ğŸ“ | |
| Information Requests (if any) | [Date] | | ğŸ“ | |
| Mid-Cycle Review | [Date] | | ğŸ“ | |
| Advisory Committee (if applicable) | [Date] | | ğŸ“ | |
| Final Decision | [Date] | | ğŸ“ | |

---

## Document Revision History

| Version | Date | Author | Description of Changes |
|---------|------|--------|------------------------|
| 1.0 | [YYYY-MM-DD] | [Name] | Initial document |
| | | | |

---

*This template is designed to assist in regulatory submission preparation and should be customized to meet specific product and submission requirements. Always refer to current regulatory authority guidelines for definitive requirements.*
